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Background: Endoscopic valve implantation is an effective treatment for patients with advanced 
emphysema. Despite the minimally invasive procedure, valve placement is associated with risks, 
the most common of which is pneumothorax. This study was designed to identify predictors of 
pneumothorax following endoscopic valve implantation.
Methods: Preinterventional clinical measures (vital capacity, forced expiratory volume in 
1 second, residual volume, total lung capacity, 6-minute walk test), qualitative computed 
tomography (CT) parameters (fissure integrity, blebs/bulla, subpleural nodules, pleural adhe-
sions, partial atelectasis, fibrotic bands, emphysema type) and quantitative CT parameters 
(volume and low attenuation volume of the target lobe and the ipsilateral untreated lobe, target 
air trapping, ipsilateral lobe volume/hemithorax volume, collapsibility of the target lobe and the 
ipsilateral untreated lobe) were retrospectively evaluated in patients who underwent endoscopic 
valve placement (n=129). Regression analysis was performed to compare those who developed 
pneumothorax following valve therapy (n=46) with those who developed target lobe volume 
reduction without pneumothorax (n=83).
Finding: Low attenuation volume% of ipsilateral untreated lobe (odds ratio [OR] =1.08, 
P=0.001), ipsilateral untreated lobe volume/hemithorax volume (OR =0.93, P=0.017), emphy-
sema type (OR =0.26, P=0.018), pleural adhesions (OR =0.33, P=0.012) and residual volume 
(OR =1.58, P=0.012) were found to be significant predictors of pneumothorax. Fissure integ-
rity (OR =1.16, P=0.075) and 6-minute walk test (OR =1.05, P=0.077) were also indicative of 
pneumothorax. The model including the aforementioned parameters predicted whether a patient 
would experience a pneumothorax 84% of the time (area under the curve =0.84).
Interpretation: Clinical and CT parameters provide a promising tool to effectively identify 
patients at high risk of pneumothorax following endoscopic valve therapy.
Keywords: endoscopic lung volume reduction, COPD, emphysema, pneumothorax, valve therapy
Introduction
Endoscopic valve therapy has evolved as a new therapeutic modality in patients with 
advanced chronic obstructive pulmonary disease (COPD) and emphysema. This tech-
nique involves the implantation of one-way valves in the emphysematous lung lobe. 
By allowing the air to exit during expiration, the valves lead to target lobe volume 
reduction (TLVR), whereby a complete lobar atelectasis represents the optimal result.
The first randomized controlled trials (RCTs), known as VENT (“Endobron-
chial Valves for Emphysema Palliation Trial”) and Euro-VENT, demonstrated 
encouraging results concerning the safety and effectiveness of this procedure.1,2 
Adverse events, including COPD exacerbations, pneumonia, mild hemoptysis, 
hypercapnia, and pneumothorax, were observed, but the rate of serious compli-
cations did not differ between the treatment and control groups. In these RCTs, 
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the pneumothorax rate was 4.2% and 4.5% at 90 days 
following the intervention.
In VENT and Euro-VENT, complete interlobar fissures 
in the preinterventional multidetector computed tomography 
(MDCT), which is a surrogate for low interlobar collateral 
ventilation, and lobar occlusion were found to be predictors 
of a meaningful clinical outcome following valve place-
ment. Therefore, only a complete occlusion of the target 
lobe in patients with low collateral ventilation was recom-
mended; this was reevaluated in two recently published 
RCTs, the BeLieVeR-HIFI study and STELVIO.3,4 These 
trials confirmed the efficacy of valve therapy but revealed 
an increased pneumothorax rate of 8%–18%. It is likely 
that a parenchymal rupture of the ipsilateral untreated lobe 
due to rapid expansion in the case of volume reduction of 
the treated lobe is the reason for the pneumothorax. In fur-
ther trials, the authors reported even higher pneumothorax 
rates of 25%, 23%, and 20%.5–7 Thus, the optimized patient 
selection is not only associated with improved outcomes 
following valve placement but also implies a higher risk of 
pneumothorax. Completeness of the fissure is particularly 
considered to support optimized outcomes as well as the 
advent of pneumothorax.
As pneumothorax seems to occur only in patients with 
significant volume shift, it is assumed that they may neverthe-
less experience good clinical outcomes in case of persistent 
TLVR after recovering from pneumothorax.8 However, 
pneumothorax presents a severe complication that frequently 
requires chest tube insertion and is associated with immobili-
zation, prolonged hospitalization, and further endoscopic or 
surgical interventions.9,10 Furthermore, tension pneumothorax 
may also present a life-threatening complication that may 
lead to a shift of the mediastinum and obstruction of venous 
return to the heart, compromising cardiovascular circum-
stances. Therefore, assessing the predictors of pneumothorax 
other than fissure integrity, which also predicts TLVR, is of 
great importance.
Methods
In this retrospective analysis, clinical and MDCT scan data 
of patients who underwent valve therapy were examined to 
determine predictors of pneumothorax following valve ther-
apy. The protocol of this retrospective analysis was approved 
by the local Ethics Committee of Heidelberg (S-609/2012). 
The majority of the patients were treated within different 
prospective trials after written informed consent. As the 
data in this current analysis were retrospectively analyzed 
no further patient consent was required.
subjects and clinical parameters
In this retrospective analysis, baseline clinical measures and 
MDCT scan data of 129 consecutive patients (mean age: 64 
years, range 43–81 years, sex: 50% male) who experienced 
TLVR (n=83) or pneumothorax (n=46) following valve 
therapy between 2009 and 2013 were assessed. The mean 
forced expiratory volume in 1 second (FEV
1
) was 0.8±0.2 
l (32%±8% predicted) and the mean residual volume (RV) 
was 5.6±1.4 l (257%±59% predicted). All the patients 
experienced a complete occlusion of the target lobe by 
endobronchial (Pulmonx, Inc., Neuchatel, Switzerland) or 
intrabronchial valves (Olympus Corporation, Tokyo, Japan) 
at the Thoraxklinik at the University of Heidelberg. Prior 
to valve therapy, MDCT, including software analysis of 
the emphysema (YACTA, “yet another CT analyser”), and 
99 m-Technetium perfusion scan were performed to iden-
tify the target lobe. Sixty-one patients (47%) experienced 
complete occlusion of the left lower lobe, 34 (26%) of the 
left upper lobe, 20 (16%) of the right upper lobe, 13 (10%) 
of the right lower lobe, and one (1%) of the right upper 
and middle lobes. TLVR was defined as lung parenchy-
mal collapse with the development of a soft-tissue dense 
atelectasis at a lobar or segmental level on a follow-up chest 
X-ray or CT scan. 
Clinical parameters prior to valve therapy and 3 months 
following pneumothorax, including vital capacity (VC), 
forced expiratory volume in 1 second (FEV
1
), residual vol-
ume (RV), total lung capacity (TLC), and the 6-minute walk 
test (6-MWT), were extracted from the patients’ records. 
Descriptive parameters (target lobe) were also evaluated.
MDCT parameters
The qualitative and quantitative MDCT parameters were 
assessed on preinterventional baseline MDCT scans 
(64-slice Somatom Definition AS64, Siemens Medical 
Solution, Forchheim, Germany); the CT protocol varied 
with reconstruction slice thickness of 1.0 (filter I40f), and 
doses of 100 kV, 117 mAs
effective
 or 120 kV, 70 mAs
effective
. 
The qualitative MDCT parameters were visually assessed 
by one experienced chest radiologist. The quantitative CT 
measurements were obtained by using syngo.via software 
(Siemens Medical Solution), which provides automated 
three-dimensional quantifications for the assessment of 
emphysema. The mean lung density of the lobes, lobar 
volumes, low attenuation volumes (LAVs) and the lobar 
collapsibility were obtained. The LAV (lung volumes with 
attenuation values ,950 Hounsfield units) and LAV% (the 
ratio of LAV to the volume of the region of interest) that 
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Table 1 Patient characteristics
Baseline clinical measures and CT parameters Patients with 
TLVR (n=83)
Patients with 
pneumothorax (n=46)
Mean ± SD Mean ± SD
Clinical variables
VC (l) 2.4±0.79 2.5±0.78
VC (%) 72.0±17.2 72.7±18.5
FeV1 (l) 0.8±0.24 0.8±0.24
FeV1 (%) 31.7±6.6 31.1±9.2
rV (l) 5.4±1.30 5.9±1.43
rV (%) 246.9±42.5 273.7±79.2
TlC (l) 7.8±1.71 8.4±1.61
TlC (%) 136.1±15.6 145.2±26.9
6-MWT (m) 281.1±107.4 305.3±93.4
Quantitative CT variables
MlD of the target lobe (hU) −916±18 −918±20
MlD of the untreated ipsilateral lobe (hU) −886±22 −893±23
Target lobe volume (ml) 1,701±466 1,831±515
Volume of the untreated ipsilateral lobe (ml) 1,629±494 1,617±456
laV of the target lobe/target lobe volume (= laV% of the target lobe) (%) 51.2±13.6 51.5±15.1
laV of the untreated ipsilateral lobe/volume of the untreated ipsilateral  
lobe (= laV% of the untreated ipsilateral lobe) (%)
31.3±11.6 37.0±12.3
Volume of the untreated ipsilateral lobe to the volume of the hemithorax 48.6±8.4 47.1±8.8
Collapsibility of the target lobe 195.5±152.1 229.4±195.3
Collapsibility of the untreated target lobe 276.0±208.6 281.0±137.8
Qualitative CT parameters
Fissure integrity (%) 97.4±5.1 98.9±2.0
Blebs/bulla – no of subjects (%) 7 (8.4) 3 (6.5)
subpleural nodules – no of subjects (%) 12 (14.5) 6 (13.0)
Pleural adhesions – no of subjects (%) 53 (63.9) 19 (41.3)
Partial atelectasis – no of subjects (%) 8 (9.6) 7 (15.2)
Fibrotic band – no of subjects (%) 29 (34.9) 15 (32.6)
Bronchiectasis – no of subjects (%) 8 (9.6) 4 (8.7)
rib fracture – no of subjects (%) 14 (16.9) 3 (6.5)
Panlobular type of emphysema – no of subjects (%) 49 (59) 22 (47.8)
Note: Plus-minus values are mean ± sD.
Abbreviations: 6-MWT, 6-minute walk test; CT, computed tomography; FeV1, forced expiratory volume in 1 second; HU, Hounsfield unit; LAV, low attenuation volume; 
MlD, mean lung density; rV, residual volume; sD, standard deviation; TlC, total lung capacity; TlVr, target lobe volume reduction; VC, vital capacity.
correlate with lung function parameters, visual CT emphy-
sema scores, and the COPD assessment test were used to 
describe the extent and severity of emphysema.11–14
statistical analysis
Univariate logistic regression models were fitted to assess the 
association between each of the 41 variables and pneumotho-
rax following valve therapy. We also assessed whether each 
continuous variable had a linear or quadratic association with 
pneumothorax in the logit scale. Stepwise forward regression 
model was fitted to assess the association between possible 
predictor variables and pneumothorax. Variables with a 
P-value ,0.5 were included in the stepwise forward regres-
sion model in the most appropriate form (linear or quadratic). 
The paired Student’s t-test was used to compare within-group 
differences in qualitative parameters. P-values ,0.05 were 
considered to be significant. Receiver operating characteristic 
curves were created using the final model of predictors.
Results
The patient charac teristics of the 83 subjects with a radiologi-
cally confirmed TLVR (Figure 1) and those of 46 patients 
who developed pneumothorax (Figure 2) are presented in 
Table 1. On the baseline MDCT scans, fissure integrity var-
ied from 80% to 100%. The fissure integrity was between 
90% and 100% in 121 patients and between 80% and 90% 
in eight patients. Overall, the median of fissure completeness 
was 100% (interquartile range 98.3 to 100).
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[OR] =1.58, P=0.012) and untreated ipsilateral lobe LAV% 
(OR =1.08, P=0.001) were associated with an increased risk of 
pneumothorax. In contrast, the presence of pleural adhesions 
(OR =0.33, P=0.012), the presence of panlobular emphy-
sema (OR =0.26, P=0.018), and the volume of the untreated 
ipsilateral lobe to the volume of the hemithorax (OR =0.93, 
P=0.017) were associated with a decreased risk of pneu-
mothorax. Finally, the 6-MWT (OR =1.05, P=0.077) and the 
fissure integrity (OR =1.16, P=0.075) tended to be associated 
with an increased risk of pneumothorax. The area under the 
curve using the full model with eight variables was 0.84. This 
indicates that it is possible to predict whether a patient would 
experience a pneumothorax 84% of the time (Figure 3).
Figure 1 Multidetector computed tomography image.
Note: lobar atelectasis of the right lower lobe following valve implantation.
Figure 2 Multidetector computed tomography image.
Notes: Pneumothorax with subsequent severe bilateral subcutaneous emphysema 
3 days following valve placement in the left lower lobe. The lung is reinflated after 
chest tube insertion.
Thirty-eight of the 46 patients (83%) who devel-
oped pneumothorax underwent chest tube insertion. 
In 18 patients (39%), valve explantation was necessary. Eight 
patients (17%) underwent additional video-assisted thoracos-
copy to seal the fistula. Three months after recovering from 
pneumothorax, patients experienced slight, but not clinically 
relevant improvements in lung function parameters, exercise 
capacity and dyspnoe score (Table 2).
After the multivariable regression analysis (Table 3), 
the LAV% of the untreated ipsilateral lobe, the volume of 
the untreated ipsilateral lobe to volume of the hemithorax, the 
predominant type of emphysema, the presence of pleural 
adhesions, and the residual volume were variables that were 
independently associated with pneumothorax, adjusting for 
the target lobe; the 6-MWT and the fissure integrity were bor-
derline non-significant. Thereby, residual volume (odds ratio 
Table 2 Clinical outcome of patients who developed pneu-
mothorax
Clinical  
parameter
n Baseline
mean ± SD
Three months following  
pneumothorax
mean ± SD
P-value
VC (l) 36 2.54±0.79 2.52±0.72 0.856
VC (%) 35 72±19 72±18 0.855
FeV1 (l) 36 0.81±0.24 0.83±0.29 0.286
FeV1 (%) 36 30±9 31±10 0.270
rV (l) 34 5.97±1.33 5.65±1.50 0.060
rV (%) 35 275±60 257±60 0.029
TlC (l) 34 8.57±1.60 8.25±1.76 0.040
TlC (%) 35 144±22 138±17 0.024
6-MWT (m) 31 320±90 330±87 0.548
mMrC (pts) 26 2.25±1.09 1.81±1.16 0.442
Note: Data were assessed 3 months following recovery from pneumothorax.
Abbreviations: 6-MWT, 6-minute walk test; FeV1, forced expiratory volume in 
1 second; rV, residual volume; sD, standard deviation; TlC, total lung capacity; VC, 
vital capacity; mMRC, modified Medical Research Council.
Table 3 Predictors for pneumothorax following valve therapy
Pneumothorax Odds 
ratio
95% 
confidence 
interval
P-value
Ipsilateral lobe laV% 1.08 1.04–1.14 0.001
Predominant type of emphysema 
(panlobular vs centrilobular)
0.26 0.09–0.74 0.018
Pleural adhesion 0.33 0.13–0.83 0.012
rV (change per unit) 1.58 1.10–2.25 0.012
Volume of the untreated ipsilateral 
lobe to the volume of the hemithorax
0.93 0.87–0.99 0.017
6-MWT (per 10 m change) 1.05 1.00–1.10 0.077
Target lobe lll (vs rUl) 0.28 0.06–1.33 0.108
Target lobe lUl (vs rUl) 0.95 0.19–4.74 0.954
Target lobe rll (vs rUl) 0.23 0.03–1.83 0.165
Fissure integrity 1.16 0.99–1.36 0.075
Abbreviations: laV, low attenuation volume; lll, left lower lobe; lUl, left upper 
lobe; rll, right lower lobe; rUl, right upper lobe; rV, residual volume; 6-MWT, 
6-minute walk test.
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Discussion
Endoscopic valve therapy has evolved as an effective therapy 
for patients with severe COPD and emphysema. It has been 
developed as a minimally invasive technique to achieve lung 
volume reduction with less morbidity and mortality than has 
been reported in lung volume reduction surgery.15 However, 
valve therapy is also associated with potential complications. 
Over the past several years, the rate of pneumothorax fol-
lowing valve insertion particularly increased due to modified 
patient selection. A complete fissure is not only a predictor of 
excellent outcome but also of pneumothorax. Pneumothorax 
occurring in 18%–25% in patients undergoing valve inser-
tion is actually the most common complication following 
valve therapy.4–7
To assess the risk of pneumothorax, we performed this 
retrospective analysis to determine the predictors of pneu-
mothorax following valve insertion. As patients with TLVR 
and pneumothorax fulfill the criterion of complete interlobar 
fissure that is regarded as a prerequisite indication for valve 
therapy, we focused on both of these patient cohorts; the 
distinction between both these groups is crucial. As a result, 
the median of fissure integrity was 100%, which explains why 
fissure integrity was not found to be a statistically significant 
predictor of pneumothorax.
In this analysis, the LAV% of the untreated ipsilat-
eral lobe, the volume of the untreated ipsilateral lobe to 
the volume of the hemithorax, the emphysema type, and 
pleural adhesions were significant CT predictors of pneu-
mothorax. The higher the emphysematous destruction of 
the untreated ipsilateral lobe, the higher the risk of pneu-
mothorax. The important role of the untreated ipsilateral 
lobe can be explained by the development of pneumothorax 
following valve implantation. It is hypothesized that pneu-
mothorax occurs by parenchymal rupture in the adjacent 
untreated lung lobe in cases of rapid TLVR. In contrast 
to expectations, panlobular emphysema was found to be 
a protective factor for the development of pneumothorax. 
Initially it was assumed that panlobular emphysema dis-
tribution would increase the risk, but exactly the opposite 
was actually found. The blebs and bullae that were assumed 
to increase the risk were also found to play no significant 
role in the development of pneumothorax. The finding of 
the protective character of a panlobular emphysema can 
not be sufficiently explained; possibly, the compliance of 
the lung tissue in the different emphysema types varies and 
may be associated with a different risk of pneumothorax. 
In addition, pleural adhesions were surprisingly found to 
be protective factors against pneumothorax. As a clinical 
predictor, the residual volume was a variable that was 
independently associated with pneumothorax, adjusting 
for the target lobe. The higher the residual volume, the 
higher the risk of pneumothorax. A high residual volume 
may be associated with a greater volume shift, increasing 
the risk of parenchymal rupture. In that model, all of these 
parameters would predict whether a patient would experi-
ence a pneumothorax 84% of the time.
One retrospective trial demonstrated that most patients 
experienced an improvement in clinical outcomes due to 
the lung volume shift despite pneumothorax.8 This finding 
was confirmed by another trial demonstrating a statistically 
beneficial outcome in patients who developed pneumothorax 
following valve therapy.16 However, only patients in whom 
lobar atelectasis could be observed after recovering from 
pneumothorax will experience an outstanding improve-
ment in lung function parameters, while patients without 
a significant TLVR following pneumothorax will experi-
ence slight but not relevant clinical improvement. In this 
analysis, no relevant clinical improvement was achieved 
after the development of a postinterventional pneumothorax, 
but pneumothorax following valve therapy did not impair 
the clinical outcome. Thus, there are some controversial 
data related to outcomes following pneumothorax in valve 
patients, but most studies suggest that patients who develop 
TLVR despite pneumothorax will benefit. However, pneu-
mothorax is associated with prolonged hospitalization 
and immobilization, leading to muscle wasting and often 
requiring further intervention, such as chest tube insertion 
or surgical intervention.
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Figure 3 rOC curve.
Note: Prediction of pneumothorax following endoscopic valve therapy using eight 
CT and clinical parameters with an aUC of 0.8367.
Abbreviations: CT, computed tomography; aUC, area under the curve; rOC, 
receiver operating characteristic.
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In one trial, bed rest and antitussive therapy successfully 
reduced the risk of pneumothorax following valve insertion.5 
Forty patients who received modified medical care, including 
48 hours of strict bed rest and 16 mg codeine if needed for 
cough up to three times a day, were compared to 32 patients 
with standard medical care following valve therapy. While 
eight patients from the standard medical care group developed 
pneumothorax during hospitalization, only two from the 
modified medical care group experienced pneumothorax 
(P=0.02). However, the number of treated patients in this 
study population was too low to allow a general statement 
for or against this modified postinterventional strategy.
Assessing the risk of pneumothorax helps to find the 
balance between efficacy and safety. Therefore, finding 
the predictors for pneumothorax is of great importance. 
The risk of pneumothorax of 18%–25% is accepted because 
the development of pneumothorax does not impair clinical 
patient outcomes. Nevertheless, the evaluation of valid 
prevention measures is crucial to minimize the risk of pneu-
mothorax that presents a severe adverse event in patients with 
advanced emphysema.
In summary, pneumothorax is a commonly anticipated 
complication of valve therapy in patients with severe emphy-
sema. Therefore, close monitoring following intervention 
is necessary. Patients with a high LAV% of the untreated 
ipsilateral lobe and a high residual volume are at particularly 
great risk of pneumothorax. A high volume of the untreated 
ipsilateral lobe compared to volume of the hemithorax, 
panlobular emphysema and pleural adhesions, however, 
were found to be protective. A thorough evaluation of the 
risks is essential to determine and discuss the therapy and 
risk–benefit profiles with the patient.
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